Posted by Michael Wonder on 25 Jul 2025
Lisocabtagene maraleucel in follicular lymphoma: mysterious study discontinuation
15 July 2025 - The BMS has not provided any study data suitable for early benefit assessment. It initiated a randomised controlled trial with a matched comparator but discontinued it for unknown reasons.
The CAR-T cell therapy lisocabtagene maraleucel is approved for the treatment of adults with relapsed or refractory follicular lymphoma who have already undergone two or more lines of systemic therapy. In an early benefit assessment, the IQWiG has investigated whether the CAR-T cell therapy offer such patients any additional benefit.
